Technical Analysis for LUMO - Lumos Pharma, Inc.
| Grade | Last Price | % Change | Price Change |
|---|---|---|---|
| D | 2.26 | -2.46% | -0.06 |
LUMO closed down 2.46 percent on Monday, July 1, 2024, on 82 percent of normal volume. The price action carved out a bearish shooting star candlestick pattern. That may indicate a downside reversal. Look for price to trade beneath the low of the shooting star for confirmation.
| ADX | Long Term | Intermediate Term | Short Term |
|---|---|---|---|
| Weak or Absent | Down | Down | Flat |
| Date | Alert Name | Type | % Chg |
|---|---|---|---|
| 20 DMA Resistance | Bearish | 0.00% | |
| Shooting Star Candlestick | Bearish | 0.00% | |
| Doji - Bearish? | Reversal | 0.00% | |
| Gapped Down | Weakness | 0.00% | |
| MACD Bullish Signal Line Cross | Bullish | -2.46% | |
| Narrow Range Bar | Range Contraction | -2.46% | |
| NR7 | Range Contraction | 0.52% | |
| NR7-2 | Range Contraction | 0.52% | |
| Narrow Range Bar | Range Contraction | 0.52% | |
| NR7 | Range Contraction | 0.35% |
| Alert | Time |
|---|---|
| 10 DMA Support | about 7 hours ago |
| Rose Above Previous Day's High | about 7 hours ago |
| Down 3% | about 7 hours ago |
| Down 2 % | about 7 hours ago |
| Down 1% | about 7 hours ago |
Get this analysis on your stocks daily!
Let us help you stay on top of your investments. We will alert you to important technical developments on your
portfolio & watchlist.
Configure default chart indicators
Basic chart:
- Earnings date: 08/07/2024
Lumos Pharma, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of therapeutics for severe, rare, and genetic diseases. Its lead therapeutic candidate LUM-201 is an oral growth hormone stimulating small molecule, which is in Phase 2 clinical trial for the treatment of pediatric growth hormone deficiency. The company has a licensing agreement with Ellipses Pharma Limited for the development of and rights to commercialize nanoparticle formulations of two therapeutics for oncology indications. Lumos Pharma, Inc. was founded in 2011 and is headquartered in Austin, Texas.
Sector: Healthcare
Industry: Biotechnology
Keywords: Biotechnology Biopharmaceutical Life Sciences Pharmacy Genetic Diseases Growth Hormone Growth Hormone Deficiency Growth Hormone Therapy
Classification
Sector: Healthcare
Industry: Biotechnology
Keywords: Biotechnology Biopharmaceutical Life Sciences Pharmacy Genetic Diseases Growth Hormone Growth Hormone Deficiency Growth Hormone Therapy
| Indicator | Bull Case | Neutral / Hold | Bear Case |
|---|---|---|---|
| 50 DMA | |||
| 200 DMA | |||
| ADX Trend | |||
| Oversold / Overbought | |||
| Relative Strength |
| Indicator | Value |
|---|---|
| 52 Week High | 4.55 |
| 52 Week Low | 2.01 |
| Average Volume | 29,173 |
| 200-Day Moving Average | 2.98 |
| 50-Day Moving Average | 2.55 |
| 20-Day Moving Average | 2.34 |
| 10-Day Moving Average | 2.25 |
| Average True Range | 0.15 |
| RSI (14) | 42.86 |
| ADX | 22.0 |
| +DI | 19.78 |
| -DI | 21.77 |
| Chandelier Exit (Long, 3 ATRs) | 2.23 |
| Chandelier Exit (Short, 3 ATRs) | 2.52 |
| Upper Bollinger Bands | 2.58 |
| Lower Bollinger Band | 2.11 |
| Percent B (%b) | 0.33 |
| BandWidth | 19.99 |
| MACD Line | -0.08 |
| MACD Signal Line | -0.08 |
| MACD Histogram | 0.0063 |
| Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
|---|---|---|---|---|---|
| Resistance 4 (R4) | 2.46 | ||||
| Resistance 3 (R3) | 2.48 | 2.43 | 2.43 | ||
| Resistance 2 (R2) | 2.43 | 2.38 | 2.42 | 2.41 | |
| Resistance 1 (R1) | 2.35 | 2.35 | 2.39 | 2.33 | 2.40 |
| Pivot Point | 2.30 | 2.30 | 2.32 | 2.29 | 2.30 |
| Support 1 (S1) | 2.22 | 2.25 | 2.26 | 2.20 | 2.12 |
| Support 2 (S2) | 2.17 | 2.22 | 2.16 | 2.11 | |
| Support 3 (S3) | 2.09 | 2.17 | 2.10 | ||
| Support 4 (S4) | 2.07 |
